Insights in Cancer Research

Editorial Panel

Nicolaas A.P. Franken
Department of Radiation Oncology, Laboratory for Experimental Oncology and Radiobiology (LEXOR), Centre of Experimental Molecular Medicine, The Netherlands
Engin Ulukaya
Prof. of Clinical Biochemistry, Medical School of Uludag University, Turkey
BiographyProf. Dr. Engin Ulukaya (MD, PhD), graduated from Cerrahpasa Medical Faculty of Istanbul University (Turkey) in 1988, became a clinical biochemist in 1995 and then gained a PhD degree in Biochemistry and Molecular Biology from University of Leeds (the UK) in 2000. He is currently a professor and working at Medical School of University of Uludag. His main research area is the relationship between cancer and cell death/apoptosis. He is especially keen on monitoring the response to chemotherapy and designing more efficient treatments for better management of cancer patients. Among his achievements is the prediction of the response to chemotherapy in cancer patients by translating basic knowledge of apoptosis into medical oncology. He is also interested in the tumor chemosensitivity assay, also called individualized tumor response test, in various solid tumor types. He is currently interested in anticancer drug development against cancer stem cells. He has a patent on novel palladium-based anticancer compounds. He is the president of association for molecular cancer research (MOKAD) in Turkey. He is also a council member of EACR (European Association for Cancer Research) as well as full member of PathoBiology group of EORTC. He was awarded as the most promising laboratory physician of the year at one of the WASPALM congresses held in South Korea in 2003. He has more than 80 publications in peer-reviewed international journals with 1704 citations (November 2015, By Google Scholar).
Marwa Amer Abd-ElMonem Amer
Icahn School of Medicine at Mount Sinai, in New York City, USA
Pasquale De Negri
IRCCS Centro di Riferimento Oncologico della Basilicata (C.R.O.B.) � Cancer Center, Department of Surgical Oncology & Pain Medicine, Italy
Giovanni Cochetti
Faculty of Medicine, University of Perugia, Italy
Chandi C Mandal
School of Life Sciences, Central University of Rajasthan, India
Karl Kingsley
Director of Student Research, University of Nevada, Las Vegas
Rachana Garg
Department of Pharmacology, University of Pennsylvania, Perelman School of Medicine, USA.
Research InterestMy research experiences have launched a long-term interest in understanding the indepth mechanisms underlying carcinogenesis, with the ultimate goal of identifying targets for drug-based therapies and developing strategies for overcoming treatment-related resistance observed in most prevalent cancer including prostate, lung and oral squamous cell carcinoma. As is evident from my educational background and trainings, my research experience spans over 15 years in the field of molecular carcinogenesis, cancer chemoprevention, cancer signaling and biochemistry. During undergraduate studies, I worked closely with oral cancer patients and detected and typed the HPV prevalence in the clinical samples. A short but an inspiring experience had made my career goal clearer and allowed me to stay focused in cancer biology field thus far. Moving ahead with my research interest, my doctoral work specifically focused on delineating the mechanism of turmeric/curcumin mediated chemoprevention in vivo model systems (liver, lung, skin and oral tissues of mice and hamsters) and to identify surrogate end point biomarkers for drug effect measurements. During my Ph.D. research, I thus gained thorough experience in working with in vivo cancer models, broadly targeting the carcinogenic process by employing chemopreventive compounds. To extensively explore the essential mechanisms in cancer development and to enhance my acquired skills in the cancer biology field, I joined the renowned signal transduction laboratory of Dr. Kazanietz at UPenn, with the main interest in protein kinase C (PKC). I have focused my postdoctoral studies largely on PKCe, a kinase that is upregulated in many epithelial cancers. Of note, the mechanism by which this kinase contributes to the initiation and maintenance of the prostate cancer phenotype is largely unknown and remains uninvestigated thus far. Using cellular, biochemical, and molecular profiling approaches, I characterized the signaling markers and molecular signature of the prostate lesions driven by PKC epsilon overexpression and Pten loss. I generated organ-specific models for transgenic expression of PKC isozymes and determined the phenotypical consequences of crossing these mice with other models harboring oncogenic alterations such as Pten and K-Ras relevant to prostate, oral and lung cancer. Furthermore, by intercrossing lung-specific mutant Ras mice (LSL-K-rasG12D) with PKCe KO mice, I demonstrated that deletion of the PKCe gene (PRKCE) in mice impaired Ras-mediated lung tumorigenesis. Using human prostate cancer clinical samples, my study established correlation of oncogenic PKC epsilon overexpression with other common alterations (Pten loss, NF-kB hyperactivation, COX-2 and CXCl13 up-regulation) in prostate cancer.
Galal Hamza Elgemeie
Faculty of Science, Helwan University, Egypt
BiographyProf. Dr. Galal H. Elgemeie was born in Egypt on July 20, 1953. He received both his B.Sc (1974) and his Ph.D. (1982) degrees from the Faculty of Science, Cairo University. He was awarded the degree of Doctor of Science (D. Sc.) in 2004. He was a postdoctoral fellow of the Alexander von Humboldt Foundation in Germany (1983-85) where he worked at Darmstadt Technical University. He also obtained the Fulbright postdoctoral fellowship at Princeton University USA (1986), the British Council postdoctoral fellowship at the University of East Anglia, England (1989), and then the German Research Foundation (DFG) fellowship at the German Cancer Research Center (DKFZ), Heidelberg, Germany (1998). He was invited to many research visits at the universities of Stuttgart, Braunschweig, Hamburg and Dusseldorf in Germany. He is an international elected member of the Scientific Board of the International Basic Sciences Programme (IBSP), UNESCO, United Nations, in Paris, France �2004-2008�. From 2011-2013, he acted as a Chairman for the Board of Directors of the Fulbright Foundation in Cairo. In 1995, he was appointed Chairman of the Chemistry Department at Helwan University in Cairo, a position he held until July 1998. He was appointed Vice Dean of the Faculty of Science at Helwan University from July 1998 until December 2005. In January 2006 until June 2009, Prof. Elgemeie was appointed to the position of Cultural Counselor and Director of the Educational Mission of the Embassy of Egypt in Berlin, Germany. He also carried out supervision of the Egyptian students in Scandinavian countries (Norway - Sweden - Denmark - Finland), Poland and the Netherlands. In October 2009 until July 2011, he was appointed Dean of the Faculty of Science at Helwan University; and from July 2011 until November 2013, he worked as the First Deputy Minister of State, Ministry of Higher Education, Egypt. Prof. Elgemeie is the author of over 200 scientific international papers on heterocyclic chemistry, medicinal chemistry and synthetic methodology. He supervised the work of 35 Ph.D and 55 M.Sc. students. His research interests cover the development and mechanistic understanding of organic reactions and their application to the synthesis of antimetabolic agents. Prof. Elgemeie is nominated as one of the leading scientists of the Member States of the Organization of Islamic Countries in the year 2009 Report. The international citation of his published work and his scientific research have been classified among the research which has most global reference in the field of chemistry and that admitted in the ISI encyclopedia as "Most Cited Chemists in the years 1982-1997". His work is cited for several international patents. He acted as a referee for many international scientific journals. He was invited to give many scientific lectures and scientific research in international universities, research centers and international conferences.
GebreYitayih Abyu
College of Health Sciences, Ayder Campus Mekelle university, Mekelle, Ethiopia
Anindya Goswami
Molecular Signal Transduction Laboratory, CSIR-Indian Institute of Integrative Medicine, India
Research Interest1. Currently my group is working in extracellular matrix proteins interaction and regulation of invasion and metastasis by targeting the following metastasis suppressors NM23H1 and KISS1. Metastatis suppressor NM-23H1, a highly downregulated protein in aggressive cancers and loss of activity of NM-23H1 promotes tumorigenesis and extracellular matrix degradation.Both of these two metastatic suppressors modulate the EMT phenotype responsible for tumor cell invasion. The transcriptional regulation of upstream factors (eg. SNAIL, Slug) are being studied for detailed exploration of metastatic cascades. 2. Prostate apoptotic response-4 (Par-4) is a naturally occurring pro-apoptotic protein, that selectively kills tumor cells when stimulated by apoptosis inducing agents. Containing two putative NLS , the SAC (selective for apoptosis in cancer) domain of Par-4 is known to inhibits NFkB transcriptional activity and induces FAS/FASL trafficking. Extracellular Par-4 have been found to exhibit antiangiogenic potential. Preliminary study reveals excellent therapeutic application of secretory Par-4 towards metastatic inhibition. Currently, we are working on extracellular matrix remodeling during metastasis and anti-invasive role of extracellular Par-4. 3. The other important tumor suppressor 4EBP1 is a major target for the recent development of target based therapeutics considering its prominent role in protein translation in malignancy. Due to hyperphosphorylation of 4EBP1, aberrant activation of downstream factors leads to autophagy and tumor progression. Employing pharmacological inhibitors /siRNA/MiRNA, we are studying the aberrant translation of oncogenic factors lead to EMT progression.
Luis Rodrigo
School of Medicine, University of Oviedo, Spain
BiographyI was born in Vitoria (Spain) on the 29th of July of 1.944. I am now 70 years old. High School studies from 1955 to 1.961. I studied at the Medical School in the Central University of Madrid, during six courses, from 1.961 to 1.967, obtaining my graduation as Licensee in Medicine and Surgery in June 67. I am Specialist in Gastroenterology through the National Program of Fellowship in the Clinic Puerta de Hierro of Madrid, from January 1.967 to December 1.971. Doctor Degree (PhD) in Medicine in Oviedo in 1.975. The title of my Doctoral Thesis was : Experimental study about the effects of prostaglandins E-1 and E-2 on the bile in the guinea-pig obtaining the Degree of Excellency. Chief of Section in Gastroenterology in the University Hospital Central of Asturias (Spain) in 1.976, and the degree of Chief of Service in 1.988, maintaining this category until now. Titular Professor in Medicine at the University of Oviedo, where I gave the theoretical and practical teaching to Medical Students from 1.983 until 2009. Full Professor in Medicine at the University of Oviedo, since 2010. We have formed around 100 Specialists in Gastroenterology in the last 42 years, within the National Program of Fellowship. Member of the Royal Academy of Medicine of Asturias (Spain), from 1.986. I am also Member of the Royal National Academy of Spain from 1998. I am and author or co-author in 245 scientific papers written in English and 282 in Spanish. I have written a total of 58 chapters of books in Gastroenterology and 8 books about Treatment in gastroenterological diseases and other digestive and liver diseases I have given many lectures all around the world and have presented about 300 Oral communications in National and International Scientific Meetings. I have participated as Main Investigator in around 45 Multicenter Clinical Trials.
Elena Ulrikh
Department of Oncology, North-Western State Medical University, Russia
Research Assistant, Mersin University, Turkey
Esther Queen Mokhuane
Department of Clinical Psychology, University of Limpopo, South Africa
Daekyu Sun
Associate Professor, Department of Pharmacology & Toxicology, College of pharmacy, BIO5 Institute, United States
Sahra Emamzadeh-Fard
Department of Radiology, Division of Interventional Radiology, Memorial Sloan-Kettering Cancer Center, New York